RhumbLine Advisers’s Natus Medical Inc NTUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-119,521
| Closed | -$3.92M | – | 3102 |
|
|
2022
Q2 | $3.92M | Buy |
119,521
+16,648
| +16% | +$526K | 0.01% | 1387 |
|
|
2022
Q1 | $2.7M | Sell |
102,873
-1,409
| -1% | -$34.4K | ﹤0.01% | 1659 |
|
|
2021
Q4 | $2.48M | Sell |
104,282
-71
| -0.1% | -$1.75K | ﹤0.01% | 1763 |
|
|
2021
Q3 | $2.62M | Sell |
104,353
-12,682
| -11% | -$323K | ﹤0.01% | 1747 |
|
|
2021
Q2 | $3.04M | Sell |
117,035
-497
| -0.4% | -$13.5K | ﹤0.01% | 1717 |
|
|
2021
Q1 | $3.01M | Buy |
117,532
+1,585
| +1% | +$40.6K | ﹤0.01% | 1703 |
|
|
2020
Q4 | $2.32M | Buy |
115,947
+11,194
| +11% | +$219K | ﹤0.01% | 1782 |
|
|
2020
Q3 | $1.79M | Sell |
104,753
-6,290
| -6% | -$119K | ﹤0.01% | 1739 |
|
|
2020
Q2 | $2.42M | Buy |
111,043
+983
| +0.9% | +$22.5K | ﹤0.01% | 1620 |
|
|
2020
Q1 | $2.55M | Buy |
110,060
+2,031
| +2% | +$59K | 0.01% | 1414 |
|
|
2019
Q4 | $3.56M | Buy |
108,029
+5,622
| +5% | +$180K | 0.01% | 1463 |
|
|
2019
Q3 | $3.26M | Buy |
102,407
+1,342
| +1% | +$39.1K | 0.01% | 1438 |
|
|
2019
Q2 | $2.6M | Buy |
101,065
+5,056
| +5% | +$129K | ﹤0.01% | 1580 |
|
|
2019
Q1 | $2.44M | Sell |
96,009
-294
| -0.3% | -$8.77K | ﹤0.01% | 1599 |
|
|
2018
Q4 | $3.28M | Buy |
96,303
+16,908
| +21% | +$550K | 0.01% | 1351 |
|
|
2018
Q3 | $2.83M | Sell |
79,395
-2,046
| -3% | -$72.2K | 0.01% | 1466 |
|
|
2018
Q2 | $2.81M | Buy |
81,441
+3,172
| +4% | +$111K | 0.01% | 1488 |
|
|
2018
Q1 | $2.63M | Buy |
78,269
+3,249
| +4% | +$103K | 0.01% | 1450 |
|
|
2017
Q4 | $2.87M | Buy |
75,020
+7,955
| +12% | +$318K | 0.01% | 1415 |
|
|
2017
Q3 | $2.52M | Buy |
67,065
+1,620
| +2% | +$57.2K | 0.01% | 1465 |
|
|
2017
Q2 | $2.44M | Sell |
65,445
-542
| -0.8% | -$19.6K | 0.01% | 1456 |
|
|
2017
Q1 | $2.59M | Buy |
65,987
+17,670
| +37% | +$663K | 0.01% | 1401 |
|
|
2016
Q4 | $1.68M | Buy |
48,317
+1,860
| +4% | +$73K | ﹤0.01% | 1553 |
|
|
2016
Q3 | $1.82M | Buy |
46,457
+2,175
| +5% | +$86.8K | 0.01% | 1462 |
|
|
2016
Q2 | $1.67M | Buy |
44,282
+1,242
| +3% | +$41.6K | 0.01% | 1462 |
|
|
2016
Q1 | $1.65M | Buy |
43,040
+190
| +0.4% | +$7.08K | 0.01% | 1498 |
|
|
2015
Q4 | $2.06M | Buy |
42,850
+4,165
| +11% | +$193K | 0.01% | 1334 |
|
|
2015
Q3 | $1.53M | Buy |
38,685
+1,193
| +3% | +$50.7K | 0.01% | 1505 |
|
|
2015
Q2 | $1.6M | Buy |
37,492
+75
| +0.2% | +$2.99K | 0.01% | 1562 |
|
|
2015
Q1 | $1.48M | Buy |
37,417
+3,790
| +11% | +$140K | ﹤0.01% | 1611 |
|
|
2014
Q4 | $1.21M | Sell |
33,627
-1,200
| -3% | -$40.3K | ﹤0.01% | 1679 |
|
|
2014
Q3 | $1.03M | Buy |
34,827
+530
| +2% | +$14.6K | ﹤0.01% | 1740 |
|
|
2014
Q2 | $862K | Sell |
34,297
-5,352
| -13% | -$132K | ﹤0.01% | 1924 |
|
|
2014
Q1 | $1.02M | Sell |
39,649
-1,080
| -3% | -$27.2K | ﹤0.01% | 1788 |
|
|
2013
Q4 | $916K | Sell |
40,729
-1,450
| -3% | -$28K | ﹤0.01% | 1878 |
|
|
2013
Q3 | $598K | Sell |
42,179
-862
| -2% | -$11.5K | ﹤0.01% | 2102 |
|
|
2013
Q2 | $588K | Buy |
+43,041
| New | +$586K | ﹤0.01% | 2141 |
|
Other funds holding NTUS
RhumbLine Advisers's NTUS Position: Q3 2022 in Review
RhumbLine Advisers sold out of Natus Medical Inc (NTUS) in Q3 2022, closing a stake of 119,521 shares — an estimated $3.92M sold.
RhumbLine Advisers first reported a position in NTUS in Q2 2013 and held it in 37 quarters. The position peaked at $3.92M in Q2 2022. 1 fund tracked by Wall St. Rank holds NTUS as of Q3 2022.
- RhumbLine Advisers reported no remaining Natus Medical Inc position as of Q3 2022 after selling out during the quarter.
- RhumbLine Advisers sold 119,521 Natus Medical Inc shares in Q3 2022, an estimated $3.92M.
- RhumbLine Advisers first reported a position in Natus Medical Inc in Q2 2013 and held it in 37 quarters.
- RhumbLine Advisers's Natus Medical Inc position peaked at $3.92M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Natus Medical Inc as of Q3 2022.
Based on RhumbLine Advisers's 13F filing for Q3 2022, filed 10 Nov 2022.